The estimated Net Worth of Joseph A. Tyndall is at least $300 mil dollars as of 1 September 2024. Joseph Tyndall owns over 11,904 units of Axogen stock worth over $299,557 and over the last 2 years Joseph sold AXGN stock worth over $0.
Joseph has made over 1 trades of the Axogen stock since 2024, according to the Form 4 filled with the SEC. Most recently Joseph exercised 11,904 units of AXGN stock worth $158,085 on 1 September 2024.
The largest trade Joseph's ever made was exercising 11,904 units of Axogen stock on 1 September 2024 worth over $158,085. On average, Joseph trades about 2,976 units every 0 days since 2022. As of 1 September 2024 Joseph still owns at least 22,557 units of Axogen stock.
You can see the complete history of Joseph Tyndall stock trades at the bottom of the page.
Joseph's mailing address filed with the SEC is C/O AXOGEN, INC. 13631 PROGRESS BLVD.,, SUITE 400, ALACHUA, FL, 32615.
Over the last 13 years, insiders at Axogen have traded over $73,805,978 worth of Axogen stock and bought 504,297 units worth $3,119,117 . The most active insiders traders include James E Deerfield Mgmt L.P...., Guido J Neels y Karen L. Zaderej. On average, Axogen executives and independent directors trade stock every 21 days with the average trade being worth of $455,132. The most recent stock trade was executed by John Johnson on 1 September 2024, trading 11,904 units of AXGN stock currently worth $158,085.
it's time to rethink nerve repair! axogen (nasdaq: axgn) is a medical products company with a portfolio of proprietary products and technologies for peripheral nerve reconstruction and regeneration. people suffer traumatic injuries or undergo surgeries that impact the function of their peripheral nerves daily. damage may cause loss of function and feeling. axogen is bringing the science of nerve repair to life with its avance® nerve graft which axogen believes is the first and only commercially available allograft for bridging nerve discontinuities, axoguard® nerve connector, a coaptation aid allowing for close approximation of severed nerves, and axoguard® nerve protector that protects nerves during the healing process.
Axogen executives and other stock owners filed with the SEC include: